Use of antipsychotic polypharmacy among patients with schizophrenia and risk of death

被引：0
|
作者：
Gasse, Christiane [1 ]
Baandrup, Lone [2 ]
Nordentoft, Merete [4 ]
Glenthoj, Birte Y. [2 ]
Lublin, Henrik [2 ]
Jensen, Vibeke Dahl [3 ]
Thomsen, Lars Krogsgaard [3 ]
Poulsen, Jan [3 ]
Mortensen, Preben B. [1 ]
机构：
[1] Univ Aarhus, Natl Ctr Register Based Res, Aarhus, Denmark
[2] Copenhagen Univ Hosp, Fac Hlth Sci, Ctr Neuropsychiat Schizophrenia Res, Glostrup, Denmark
[3] Danish Med Agcy, Copenhagen, Denmark
[4] Copenhagen Univ Hosp, Dept Psychiat, Bispebjerg, Denmark
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2008年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
465
引用
收藏
页码：S204 / S205
页数：2
相关论文
共 50 条
  • [21] Switching antipsychotic polypharmacy to monopharmacy in patients with schizophrenia - The Third Report
    Suzuki, T
    Watanabe, K
    Arai, T
    Hosogane, N
    Tanaka, K
    Oda, K
    Nomura, K
    Yagi, G
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2002, 17 : S16 - S16
  • [22] Antipsychotic polypharmacy among elderly patients with schizophrenia and dementia during hospitalization at a Taiwanese psychiatric hospital
    Wu, Yu-Hsuan
    Lai, Chun-Yang
    Chang, Yu-San
    PSYCHOGERIATRICS, 2015, 15 (01) : 7 - 13
  • [23] Prescription Patterns for Patients with Schizophrenia in Korea: A Focus on Antipsychotic Polypharmacy
    Kim, Hee-Yun
    Lee, Hee-Won
    Jung, Seung-Ho
    Kang, Min-Hee
    Bae, Jae-Nam
    Lee, Jeong-Seop
    Kim, Chul-Eung
    CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2014, 12 (02) : 128 - 136
  • [24] Clinical and social determinants of antipsychotic polypharmacy for Chinese patients with schizophrenia
    Xiang, Y.-T.
    Weng, Y.-Z.
    Leung, C.-M.
    Tang, W.-K.
    Ungvari, G. S.
    PHARMACOPSYCHIATRY, 2007, 40 (02) : 47 - 52
  • [25] Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia
    Suzuki, T
    Uchida, H
    Tanaka, KF
    Nomura, K
    Takano, H
    Tanabe, A
    Watanabe, K
    Yagi, G
    Kashima, H
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 (02): : 133 - 142
  • [26] Antipsychotic Polypharmacy and Risk of Death From Natural Causes in Patients With Schizophrenia: A Population-Based Nested Case-Control Study
    Baandrup, Lone
    Gasse, Christiane
    Jensen, Vibeke D.
    Glenthoj, Birte Y.
    Nordentoft, Merete
    Lublin, Henrik
    Fink-Jensen, Anders
    Lindhardt, Anne
    Mortensen, Preben B.
    JOURNAL OF CLINICAL PSYCHIATRY, 2010, 71 (02) : 103 - 108
  • [27] Long term antipsychotic polypharmacy is common among Medicaid recipients with schizophrenia
    Ganguly, R.
    Kotzan, J. A.
    Miller, L. S.
    Martin, Dr Bradley C.
    EVIDENCE-BASED MENTAL HEALTH, 2005, 8 (02) : 55 - 55
  • [28] Regional variation in antipsychotic polypharmacy for schizophrenia
    Baandrup, Lone
    EVIDENCE-BASED MENTAL HEALTH, 2011, 14 (03) : 68 - 68
  • [29] Cost of antipsychotic polypharmacy in the treatment of schizophrenia
    Zhu, Baojin
    Ascher-Svanum, Haya
    Faries, Douglas E.
    Correll, Christoph U.
    Kane, John M.
    BMC PSYCHIATRY, 2008, 8 (1)
  • [30] Trends in and Predictors of Long-Term Antipsychotic Polypharmacy Use Among Ohio Medicaid Patients with Schizophrenia, 2008-2014
    Fontanella, Cynthia A.
    Hiance-Steelesmith, Danielle L.
    Guirgis, Hossam
    Campo, John V.
    PSYCHIATRIC SERVICES, 2018, 69 (09) : 1015 - 1020
12345